文献速递血管炎

白细胞介素-6受体编码单核苷酸多态性增强巨细胞动脉炎CD4 T细胞IL-6信号传导并预测托珠单抗治疗反应

A coding single nucleotide polymorphism in the interleukin-6 receptor enhances IL-6 signalling in CD4 T cells and predicts treatment response to tocilizumab in giant cell arteritis.
PubMed 文献 · Ann Rheum Dis · 2025-02-24

在2个独立巨细胞动脉炎(GCA)队列中检测IL-6受体rs2228145多态性,衍生队列58例中纯合子患者托珠单抗反应率36%、无变异者95%(P=.003),验证队列42例分别为50%和85%(P=.04);该变异通过增强CD4 T细胞对IL-6的反应与治疗反应降低相关。

要点

  • rs2228145变异在衍生和验证队列中均预测托珠单抗反应。
  • 衍生队列纯合子反应率36% vs 无变异者95%(P=.003)。
  • 验证队列纯合子反应率50% vs 无变异者85%(P=.04)。

核心结论

  • rs2228145变异与GCA中托珠单抗治疗反应降低和更差结局相关,机制为增强CD4 T细胞对IL-6的反应。

研究设计与样本

  • 对2个独立GCA患者队列进行rs2228145位点基因测序,共纳入100例患者(衍生队列n=58,验证队列n=42)。
  • 用流式细胞术检测患者和对照外周血单个核细胞(PBMC)中IL-6R及其共受体gp130的表达。
  • 用IL-6刺激PBMC并评估下游靶点STAT3磷酸化(pSTAT3)和IL-17A表达。

主要发现

  • 衍生队列中观察到基因剂量依赖性反应,纯合子患者反应率36%,无变异患者反应率95%(P=.003)。
  • 验证队列中托珠单抗反应率纯合子为50%,无变异患者为85%(P=.04)。
  • GCA患者CD4 T细胞中IL-6刺激后pSTAT3水平呈基因剂量依赖性显著升高,对照者无此现象。
  • GCA患者CD4 T细胞膜gp130表达显著高于健康对照,且对IL-6的反应与gp130表达相关。
  • 产生IL-17的CD4 T细胞对IL-6呈基因剂量依赖性增加(P<.01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The study objective was to determine if a common single nucleotide polymorphism in the interleukin 6 (IL-6) receptor (rs2228145, p.Asp358Ala) predicted treatment response to tocilizumab in giant cell arteritis (GCA). METHODS: Genetic sequencing of the rs2228145 locus was performed in 2 independent cohorts of patients with GCA. Peripheral blood mononuclear cells (PBMCs) from patients and controls were evaluated for expression of the interleukin 6 receptor (IL-6R) and its coreceptor, gp130, using flow cytometry. The same PBMCs were stimulated with IL-6 and evaluated for downstream targets of IL-6: STAT3 phosphorylation (pSTAT3) and IL-17A expression. RESULTS: In total, 100 patients with GCA were included (derivation cohort n = 58; validation cohort n = 42). The rs2228145 variant predicted tocilizumab response in each cohort. In the derivation cohort, a gene dose-dependent response was observed with a 36% response rate in the homozygous patients and 95% response rate in patients without the variant (P = .003). In the validation cohort, tocilizumab response rates were 50% for homozygotes and 85% for patients without the variant (P = .04). pSTAT3 levels were significantly increased in response to IL-6 stimulation in a gene dose-dependent manner in CD4 T cells from patients with GCA but not controls. CD4 T cells from patients with GCA had significantly higher membrane expression of gp130 than healthy controls, and response to IL-6 correlated with gp130 expression. IL-17 producing CD4 T cells were increased in a gene dose-dependent response to IL-6 (P < .01). CONCLUSIONS: The rs2228145 variant is associated with decreased treatment response to tocilizumab and worse outcomes in GCA by enhancing CD4 T cell response to IL-6.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Zorc R, Redmond C, Sylvester M, et al. A coding single nucleotide polymorphism in the interleukin-6 receptor enhances IL-6 signalling in CD4 T cells and predicts treatment response to tocilizumab in giant cell arteritis. Ann Rheum Dis. 2025. PMID: 40000263. doi:10.1016/j.ard.2025.01.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。